Drug intelligence / Profile preview

AMDX-9101

Development stage: Preclinical
Modality: Small Molecules
Administration: Ophthalmic

Overview

AMDX-9101 is a novel small-molecule fluorescent ocular tracer developed for the detection of transthyretin (TTR) amyloid in the conjunctiva. It exhibits hyper-fluorescence when incubated with TTR protein aggregates in vitro and labels TTR amyloid deposits in postmortem human conjunctiva and other ocular tissues. The fluorescent binding signal can be visualized using commercially available ophthalmic imaging equipment, offering a potential new and noninvasive diagnostic test for transthyretin amyloidosis (ATTR) to facilitate earlier diagnosis and therapeutic development.

Targets

TTR amyloid fibril (Transthyretin amyloid fibril)

Beyond the preview

Go deeper on AMDX-9101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMDX-9101.

Explore the full profile